Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234862 | 0.86 | PDE4A (0.48) | PDE4APDE4DPDE4BPDE4CHCRTR1 | |
| SCHEMBL3263130 | 0.84 | PDE4A (0.52) | PDE4APDE4DPDE4BPDE4CGAK | |
| SCHEMBL3239951 | 0.84 | PDE4A (0.52) | PDE4APDE4DPDE4BPDE4CGAK | |
| SCHEMBL3236840 | 0.83 | PDE4A (0.48) | PDE4APDE4DPDE4BPDE4CHCRTR1 | |
| SCHEMBL3236855 | 0.82 | PDE4A (0.48) | PDE4APDE4DPDE4BPDE4CFPR2 | |
| SCHEMBL3260692 | 0.82 | PDE4A (0.48) | PDE4APDE4DPDE4BPDE4CGAK | |
| SCHEMBL3234463 | 0.81 | PDE4A (0.48) | PDE4APDE4DPDE4BPDE4CFPR2 | |
| SCHEMBL3240498 | 0.81 | PDE4A (0.48) | PDE4APDE4DPDE4BPDE4CGAK | |
| SCHEMBL3234470 | 0.80 | PDE4A (0.47) | PDE4APDE4DPDE4BPDE4CFPR2 | |
| SCHEMBL3236235 | 0.80 | PDE4A (0.48) | PDE4APDE4DPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010029299-A1 | PYRIMIDINONE DERIVATIES FOR USE AS MEDICAMENTS | BIOLIPOX AB (SE) | 2010-03-18 | — | — | WO | disclosed |